ANI Pharmaceuticals, Inc.
ANIP
$63.26
$1.863.03%
| Weiss Ratings | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | D+ | |||
| Rating Factors | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.55 | |||
| Price History | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 8.21% | |||
| 30-Day Total Return | 7.01% | |||
| 60-Day Total Return | 6.91% | |||
| 90-Day Total Return | 7.20% | |||
| Year to Date Total Return | 14.11% | |||
| 1-Year Total Return | -4.93% | |||
| 2-Year Total Return | 54.26% | |||
| 3-Year Total Return | 77.40% | |||
| 5-Year Total Return | 80.69% | |||
| 52-Week High % Change | -13.29% | |||
| 52-Week Low % Change | 16.95% | |||
| Price | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $70.81 | |||
| 52-Week Low Price | $52.50 | |||
| 52-Week Low Price (Date) | Dec 19, 2024 | |||
| 52-Week High Price (Date) | Mar 25, 2024 | |||
| Valuation | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.25B | |||
| Enterprise Value | 1.75B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.04 | |||
| Earnings Per Share Growth | -224.65% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.94 | |||
| Price/Book (Q) | 2.99 | |||
| Enterprise Value/Revenue (TTM) | 2.85 | |||
| Price | $63.26 | |||
| Enterprise Value/EBITDA (TTM) | 21.27 | |||
| Enterprise Value/EBIT | 119.80 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 19.45M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -8.77% | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 218 634 3500 | |||
| Address | 210 Main Street West Baudette, MN 56623 | |||
| Website | www.anipharmaceuticals.com | |||
| Country | United States | |||
| Year Founded | 2001 | |||
| Profitability | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 2.37% | |||
| Profit Margin | -3.01% | |||
| Management Effectiveness | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 0.84% | |||
| Return on Equity | -- | |||
| Income Statement | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 614.38M | |||
| Total Revenue (TTM) | 614.38M | |||
| Revenue Per Share | $31.60 | |||
| Gross Profit (TTM) | 364.17M | |||
| EBITDA (TTM) | 82.35M | |||
| EBIT (TTM) | 14.62M | |||
| Net Income (TTM) | -18.52M | |||
| Net Income Avl. to Common (TTM) | -20.15M | |||
| Total Revenue Growth (Q YOY) | 44.75% | |||
| Earnings Growth (Q YOY) | -989.70% | |||
| EPS Diluted (TTM) | -1.04 | |||
| EPS Diluted Growth (Q YOY) | -1,604.93% | |||
| Balance Sheet | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 151.17M | |||
| Cash Per Share (Q) | $7.77 | |||
| Total Current Assets (Q) | 527.68M | |||
| Total Preferred Equity (Q) | 24.85 | |||
| Total Equity (Q) | 428.53M | |||
| Current Ratio (Q) | 2.725 | |||
| Book Value Per Share (Q) | $20.54 | |||
| Total Assets (Q) | 1.28B | |||
| Total Current Liabilities (Q) | 193.68M | |||
| Total Debt (Q) | 630.68M | |||
| Total Liabilities (Q) | 855.17M | |||
| Total Common Equity (Q) | 403.68M | |||
| Cash Flow | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -404.72M | |||
| Cash from Financing (TTM) | 264.95M | |||
| Net Change in Cash (TTM) | -76.23M | |||
| Levered Free Cash Flow (TTM) | 30.13M | |||
| Cash from Operations (TTM) | 64.02M | |||
